Antiviral agents for herpes simplex virus

Advances in Pharmacology

Volumn 67, Issue , 2013, Pages 1-38

  Vere Hodge, R Anthony ^a   Field, Hugh J ^b  

^a Vere Hodge Antivirals Ltd   (United Kingdom)

^b QUEENS COLLEGE   (United Kingdom)

Author keywords

Antiviral chemotherapy; CMX001; Famciclovir; HSV; Pritelivir; Valacyclovir

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ACICLOVIR PLUS HYDROCORTISONE; AIC 316; AMENAMEVIR; ANTIVIRUS AGENT; BAY 571293; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; DNA PRIMASE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HELICASE; OMACICLOVIR; PENCICLOVIR; PLACEBO; PRITELIVIR; PRODRUG; SORIVUDINE; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VALOMACICLOVIR;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHEMOTHERAPY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GANGLION; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LATENT PERIOD; MONONUCLEOSIS; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT INFECTION; VACCINATION; VIRAL GENETICS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING;

EID: 84880579233     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405880-4.00001-9     Document Type: Chapter

References (81)

1. Abudalu M., Tyring S., Koltun W., Bodsorth N., Hamed K. Single-day patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: A randomized, double-blind, comparative trial. Clinical Infectious Diseases 2008, 47:651-658.
2. Ahmed A., Woolley P.D. Comparison of famciclovir and valaciclovir in first episode genital herpes: Possible clinical effect of latency 1996.
3. Anderson B.J. Prophylactic valacyclovir to prevent outbreaks of primary herpes gladiatorum at a 28-day wrestling camp. Japanese Journal of Infectious Diseases 2006, 59:6-9.
4. Aoki F.Y., Tyring S., Diaz-Mitoma F., Gross G., Gao J., Hamed K. Single-day, patient-initiated famclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases 2006, 42:8-13.
5. Bacon T.H., Boon R.J., Schultz M., Hodges-Savola C. Surveillance for antiviral-agent-resistant herpes simplex virus in general population with recurrent herpes labialis. Antimicrobial Agents and Chemotherapy 2002, 46:3042-3044.
6. Bacon T.H., Levin M.J., Leary J.J., Sarisky R.T., Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clinical Microbiology Reviews 2003, 16:114-128.
7. Bacon T.H., Schinazi R.F. An overview of the further evaluation of penciclovir against herpes simplex virus and varicella-zoster virus in cell culture highlighting contrasts with acyclovir. Antiviral Chemistry & Chemotherapy 1993, 4(Suppl. 1):25-36.
8. Balfour H.H., Vezina H.E., Hogquist K.A., Brundagem R.C., Andersonm R.J., Odumade O.A. Randomized, placebo-controlled, double-blind trial of valomaciclovir (VALM) for infectious mononucleosis (IM) 2009, Abstract LB-3498.
9. Birkmann A., Kropeit D., Biswas S., Paulsen D., Sukla S., Field H.J. PK/PD evaluation of AIC316, a novel herpes simplex virus inhibitor currently in clinical development 2010.
10. Boon R.J., Bacon T.H., Robey H.L., Coleman T.J., Connolly A., Crosson P., et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: A UK-based survey. The Journal of Antimicrobial Chemotherapy 2000, 46:324-325.
11. Cernik C., Gallina K., Brodell R.T. The treatment of herpes simplex infections: An evidence-based review. Archives of Internal Medicine 2008, 168:1137-1144.
12. Chatis P.A., Crumpacker C.S. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 1991, 180:793-797.
13. Chatis P.A., Miller C.H., Schrager L.E., Crumpacker C.S. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. The New England Journal of Medicine 1989, 320:297-300.
14. Christophers J., Clayton J., Craske J., Ward R., Collins P., Trowbrige M., et al. Survey of resistance of herpes simplex virus to acyclovir in North-west England. Antimicrobial Agents and Chemotherapy 1998, 42:868-872.
15. Christophers J., Sutton R.N. Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient. The Journal of Antimicrobial Chemotherapy 1987, 20:389-398.
16. Christophers J., Sutton R.N., Noble R.V., Anderson H. Clinical resistance to acyclovir of herpes simplex virus infections in immunocompromised patients. The Journal of Antimicrobial Chemotherapy 1986, 18(Suppl. B):121-125.
17. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. The New England Journal of Medicine 2004, 350:11-20.
18. Crumpacker C.S., Schnipper L.E., Zaia J.A., Levin M.J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrobial Agents and Chemotherapy 1979, 15:642-645.
19. Cunningham A., Griffiths P., Leone P., Mindel A., Patel R., Stanberry L., et al. Current management and recommendations for access to antiviral therapy of herpes labialis. Journal of Clinical Virology 2012, 53:6-11.
20. Datema R., Ericson A.-C., Field H.J., Larsson A., Stenberg K. Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs. Antiviral Research 1987, 7:303-316.
21. Davison A.J. Introduction: Definition and classification of the human herpesviruses, comparative analysis of the genomes. Human herpesviruses: Biology, therapy and immunoprophylaxis 2007, 10-26. Cambridge University Press, Cambridge. A. Arvin, G. Campidelli-Fiume, E. Mocarski, P.S. Moore, B. Roizman, R. Whitley, K. Yamanishi (Eds.).
22. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clinical Microbiology Reviews 2003, 16:569-596.
23. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323:464-467.
24. Diaz-Mitoma F., Sibbald R.G., Shafran S.D., Boon R.L., Saltzman M.D. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. Journal of the American Medical Association 1998, 280:887-892.
25. Duan R., de Vries R.D., Osterhaus A.D.M.E., Remeijer L., Verjans G.M. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. The Journal of Infectious Diseases 2008, 198:659-663.
26. Earnshaw D.L., Bacon T.H., Darlison S.J., Edmonds K., Perkins R.M., Vere Hodge R.A. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrobial Agents and Chemotherapy 1992, 36:2747-2757.
27. Earnshaw D.L., Vere Hodge R.A. 1992, Abstract 1707.
28. Efstathiou S., Field H.J., Griffiths P.D., Kern E.R., Sacks S.L., Sawtell N.M., et al. Herpes simplex virus latency and nucleoside analogues. Antiviral Research 1999, 41:85-100.
29. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences of the United States of America 1977, 74:5716-5720.
30. Evans T.G., Bernstein D.I., Raborn G.W., Harmenberg J., Kowalski J., Spruance S.L. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrobial Agents and Chemotherapy 2002, 46:1870-1874.
31. Farooq A.V., Shukla D. Herpes simplex epithelial and stromal keratitis: An epidemiologic update. Survey of Ophthalmology 2012, 57:448-462.
32. Fatahzadeh M., Schwartz R.A. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. Journal of the American Academy of Dermatology 2007, 57:737-763.
33. Field H.J. Herpes simplex virus antiviral drug resistance-Current trends and future prospects. Journal of Clinical Virology 2001, 21:261-269.
34. Field H.J., Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resistance Updates 2011, 14:45-51.
35. Field H.J., Mickleburgh I. The helicase-primase complex as a target for effective herpesvirus antivirals. Advances experimental medical biology 2013, Vol. 767:145-159. Springer, New York, USA. M. Spies (Ed.).
36. Field H.J., Tewari D., Sutton D., Thackray A.M. Comparison of efficacies of famciclovir and valacyclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrobial Agents and Chemotherapy 1995, 39:1114-1119.
37. Field H.J., Thackray A.M. Early therapy with valacyclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency. Nucleosides, Nucleotides & Nucleic Acids 2000, 19:461-470.
38. Field H.J., Vere Hodge R.A. Recent developments in anti-herpesvirus agents. British Medical Bulletin 2013, 1-37. 10.1093/bmb/ldt011.
39. Gershon A.A. Varicella zoster vaccines and their implications for the development of HSV vaccines. Virology 2013, 435:29-36.
40. Gilbert M., Li X., Petric M., Krajden M., Isaac-Renton J.L., Ogilvie G., et al. Using centralized laboratory data to monitor trends in herpes simplex virus type 1 and 2 infection in British Columbia and the changing etiology of genital herpes. Canadian Journal of Public Health 2011, 102:225-229.
41. GlaxoSmithkline Beecham. (2011). Highlights of prescribing information. GlaxoSmithKline Research, Triangle Park, NC, USA.
42. Goldner T., Hewlett G., Ettischer N., Ruebsamen-Schaeff H., Zimmermann H., Lischka P. The novel anticytomegalovirus compound AIC246 (letermovir) Inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. Journal of Virology 2011, 85:10884-10893.
43. Gronseth G.S., Paduga R. American Academy of Neurology: Report of the Guideline Development Subcommittee of the evidence-based guideline update: Steroids and antivirals for Bell palsy. Neurology 2012, 79:2209-2213.
44. Hamzeh F.M., Schaad H.J., Lietman P.S. 1995, Santa Fe, New Mexico, USA, Abstract.
45. Harmenberg J., Oberg B., Spruance S. Prevention of ulcerative lesions by episodic treatment or recurrent herpes labialis: A literature review. Acta Dermato-Venereologica 2010, 90:122-130.
46. Hull C.M., Brunton S. The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese) in the treatment of recurrent herpes simplex labialis. Postgraduate Medicine 2010, 122:1-6.
47. Itzhaki R. Herpes simplex virus type 1, apolipoprotein E and Alzheimer's disease. Herpes 2004, 11(Suppl. 2):77A-82A.
48. Jarvest R.L., Sutton D., Vere Hodge R.A. Famciclovir: Discovery and development of a novel antiherpesvirus agent. Integration of pharmaceutical discovery and development: Case studies 1998, 313-343. Plenum Press, New York. R.T. Borchardt, R.M. Friedinger, T. Sawyer, P. Smith, R.T. Borchardt, R.M. Friedinger, T. Sawyer, P. Smith (Eds.).
49. Laferty W.E., Coombs R.W., Benedetti J., Critchlow C., Corey L. Recurrences after oral and genital herpes simplex virus infection: Influence of anatomic site and viral type. The New England Journal of Medicine 1987, 316:1444-1449.
50. Larsson A., Stenberg K., Ericson A.-C., Haglund U., Yisak W.-A., Johansson N.G., et al. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrobial Agents and Chemotherapy 1986, 30:598-605.
51. LeBlanc R.A., Pesnicak L., Godleski M., Straus S.E. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. The Journal of Infectious Diseases 1999, 180:594-599.
52. Mindel A., Faherty A., Carney O., Patou G., Freris M., Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988, 1:926-928.
53. Pebody R.G., Andrews N., Brown D., Gopal R., de Melker H., Francois G., et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sexually Transmitted Infections 2004, 80:185-191.
54. Piret J., Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrobial Agents and Chemotherapy 2011, 55:459-472.
55. Reyes M., Shaik N.S., Graber J.M., Nisenbaum R., Wetherall N.T., Fukuda K., et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Archives of Internal Medicine 2003, 163:76-80.
56. Clinical virology 2010, ASM Press, Washington, DC. 3rd ed. D.D. Richman, R.J. Whitley, F.G. Hayden (Eds.).
57. Sailer C.A., Spruance S.L., Hull C.M. Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores. Virus Adaptation and Treatment 2011, 3:1-6.
58. Sakuma S., Yamamoto M., Kumano Y., Mori R. An acyclovir resistant strain of herpes simplex virus type 2 which is highly virulent for mice. Archives of Virology 1988, 101:169-182.
59. Sawtell N.M. Comprehensive quantification of herpes simplex virus latency at the single-cell level. Journal of Virology 1997, 71:5423-5431.
60. Skelly M.J., Burger A.A., Adekola O. Herpes simplex virus encephalitis: A review of current disease management with three case reports. Antimicrobial Agents and Chemotherapy 2012, 23:13-18.
61. Spruance S.L., Bodsworth N., Resnick H., Conant M., Oeuvray C., Gao J., et al. Single-dose, patient-initiated famciclovir: A randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. Journal of the American Academy of Dermatology 2006, 55:47-53.
62. Studdiford J.S., Valko G.P., Belin L.J., Stonehouse A.R. Eczema herpeticum: Making the diagnosis in the emergency department. The Journal of Emergency Medicine 2011, 40:167-169.
63. Sutton D., Kingsley S.D., Wells G.I., Bartus H.R., Esser K.M. Famciclovir treatment of acute herpes simplex virus infection in mice reduces the subsequent frequency of latent virus reactivation induced by transitory hyperthermia [Abstract 135]. Antiviral Research 1998, 37:A38.
64. Thackray A.M., Field H.J. Differential effects of famciclovir and valacyclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. The Journal of Infectious Diseases 1996, 173:291-299.
65. Thackray A.M., Field H.J. The influence of cyclosporin immunosuppression on the efficacy of famciclovir or valaciclovir chemotherapy studied in a murine herpes simplex virus type 1 infection model. Antiviral Chemistry & Chemotherapy 1997, 8:317-326.
66. Thompson R.L., Sawtell N.M. Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral copy genome copy number latency. Journal of Virology 1999, 74:965-974.
67. Tyring S.K., Diaz-Mitoma F., Shafran S.D., Locke L.A., Sacks S.L., Young C.L. Oral famciclovir for the suppression of recurrent genital herpes: The combined data from two randomized controlled trials. Journal of Cutaneous Medicine and Surgery 2003, 7:449-454.
68. Tyring S.K., Plunkett S., Scribner A.R., et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. Journal Medical Virology 2012, 84:1224-1232.
69. Vere Hodge R.A. A mechanism for famciclovir disabling the establishment of herpesvirus latency: A hypothesis. Antiviral research 1999, Vol. 41:A64.
70. Vere Hodge R.A. Scientific report: Highlights of 25th ICAR, 16-19 April 2012, Sapporo, Japan. Antiviral Chemistry & Chemotherapy 2012, 23:19-33.
71. Vere Hodge R.A., Field H.J. Genetics and evolution of infectious diseases (Chapter 13). Genetics and Evolution of Infectious Diseases, 2011 2011, 338-362. Elsevier, London, UK and Burlington, MA, USA. M. Tibayrenc (Ed.).
72. Vere Hodge R.A., Perkins R.M. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrobial Agents and Chemotherapy 1989, 33:223-229.
73. Vere Hodge R.A., Sutton D., Boyd M.R., Harnden M.R., Jarvest R.L. Selection of an oral prodrug (BRL 42810: famciclovir) for the antiherpesvirus agent BRL 39123 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine: Penciclovir. Antimicrobial Agents and Chemotherapy 1989, 33:1765-1773.
74. Wagstaff A.J., Bryson H.M. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994, 48:199-226.
75. Wald A., Stoellben S., Tyring S., Warren T., Johnston C., Huang M.L., et al. Impact of AIC316, a novel antiviral helicase-primase inhibitor, on genital HSV shedding: Randomized, double-blind, placebo-controlled trial 2011.
76. Wald A., Zeh J., Selke S., Ashley R.L., Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. The New England Journal of Medicine 1995, 333:770-775.
77. Watkins A.M., Dunford P.J., Moffatt A.M., Wong-Kai-In P., Holland M.J., Pole D.S., et al. Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. Antiviral Chemistry & Chemotherapy 1998, 9:9-18.
78. Whitley R. Neonatal herpes simplex virus infection. Current Opinion in Infectious Diseases 2004, 17:243-246.
79. Whitley R.J. Herpes simplex encephalitis: Adolescents and adults. Antiviral Research 2006, 71:141-148.
80. Wollenberg A., Zoch C., Wetzel S., Plewig G., Przybilla B. Predisposing factors and clinical features of eczema herpeticum: A retrospective analysis of 100 cases. Journal of the American Academy of Dermatology 2003, 49:198-205.
81. Zhu L.A., Weller S.K. The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase primase, are essential for its function. Journal of Virology 1992, 66:469-479.